Synthesis and Cytotoxicity of Coumarin Derivatives and Nordentatin

PAWANTREE PROMSUWAN and CHAVI YENJAI*

Natural Products Research Unit, Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen 40002, Thailand

*Corresponding author: Fax: +66 4320 2373; Tel: +66 4320 2222-41, Ext. 12243; E-mail: chayen@kku.ac.th

(Received: 6 March 2012;

Accepted: 7 January 2013)

AJC-12664

Nordentatin and 10 coumarin derivatives were synthesized and evaluated for cytotoxicity. Compounds **6**, **7**, **9** and **13** showed cytotoxicity against the NCI-H187 cell line with IC_{50} value ranging of 3-7 $\mu\text{g/mL}$. Among synthesized coumarins, compounds **4** and **13** demonstrated cytotoxicity against the KB cell line with IC_{50} values of 3.94 and 6.44 $\mu\text{g/mL}$, respectively. Fortunately, coumarins **4** and **7** may be one of the new lead compounds for the development of anticancer agents due to reason that they showed weak and inactive against normal cells.

Key Words: Nordentatin, Cytotoxicity, NCI-H187, KB, MCF-7, Vero cells.

INTRODUCTION

In continuation of our work on bioactive substances from natural sources, we have intensively screened the bioactivities of plants in Thailand. Structural modification of natural compounds such as flavonoids¹, sesquiterpenes² and carbazoles³ have been studied and evaluated for bioactivities. In previous investigations of the chemical constituents of *Clausena harmandiana*, carbazoles and coumarins have been isolated and evaluated for many activities such as antiplasmodial⁴, antifungal, anti TB, cytotoxic^{5,6} and antidiabetic⁷. It has been reported that coumarins exhibit antibacterial and antitumor promoting action and have an inhibitory effect on iNOS protein expression⁸. Nordentatin, a coumarin from this plant, showed significant glucose uptake activity in L9 myotubes in a time and dose dependent manner⁷. In addition, nordentatin was inhibited by phosphatidylinositol 3-kinases and showed significant toxicity to P-388 cells with EC_{50} value of 0.26 mg/mL ⁹. It has been reported that this compound shows antibacterial activity and displays more potent NO-reducing activity in microglial cells¹⁰. This compound suppressed hepatitis B virus surface antigen in HepA2 cells and showed cytotoxicity against human cancer cells, A549¹¹. In the present work, we tried to synthesize nordentatin from 5,7-dimethoxycoumarin which was obtained from the reaction of phloroglucinol (**1**) and ethyl propiolate (**2**). All coumarin derivatives obtained from the reactions were evaluated for cytotoxicity against cancer cells, NCI-H187, MCF-7 and KB cell lines and non-cancer cell, Vero cells (Table-1).

TABLE-1
CYTOTOXICITY OF ALL COMPOUNDS

Compound	Cytotoxicity (IC_{50} $\mu\text{g/mL}$)			
	NCI-H187	MCF-7	KB	Vero cells
3	Inactive ^a	Inactive ^a	Inactive ^a	Inactive ^a
4	34.95	Inactive ^a	3.94	47.04
5	11.31	Inactive ^a	48.29	41.45
6	5.18	18.65	14.42	18.27
7	5.78	Inactive ^a	17.34	Inactive ^a
8	Inactive ^a	Inactive ^a	21.48	19.14
9	7.39	21.52	12.49	17.20
10	Inactive ^a	Inactive ^a	Inactive ^a	Inactive ^a
11	13.90	22.55	26.00	21.83
12	13.60	25.84	25.53	24.87
13	3.69	10.68	6.44	17.60
Ellipticine	1.05	—	1.27	1.02
Doxorubicin	—	8.02	—	—

*Data shown are from triplicate experiments. ^aInactive at $> 50 \mu\text{g/mL}$.

EXPERIMENTAL

NMR spectra were recorded on a Varian Mercury plus spectrometer operating at 400 MHz (^1H) and at 100 MHz (^{13}C). IR spectra were recorded as KBr disks using a Perkin Elmer Spectrum One FT-IR spectrophotometer. Mass spectra were determined on a Micromass Q-TOF 2 hybrid quadrupole time-of-flight (Q-TOF) mass spectrometer with a Z-spray ES source (Micromass, Manchester, UK). Melting points were determined on a SANYO Gallenkamp melting point apparatus and were uncorrected. Thin layer chromatography (TLC) was carried out on MERCK silica gel 60 F₂₅₄ TLC aluminum sheet.

Column chromatography was done with silica gel 0.063-0.200 mm or less than 0.063 mm. Preparative layer chromatography was carried out on glass supported silica gel plates using silica gel 60 PF₂₅₄ for preparative layer chromatography. All solvents were routinely distilled prior to use.

Synthesis

5,7-Dihydroxycoumarin (3): A mixture of phloroglucinol (1) (2.00 g, 15.8 mmol), ZnCl₂ (1.67 g, 12.3 mmol) and ethyl propionate (2) (1.9 mL) was mixed together and stirred for 2 h at 100 °C. Then the mixture was cooled and 5 % hydrochloric acid (40 mL) was added. The precipitate was filtered off and washed with boiling H₂O and purified by flash column chromatography using 10 % MeOH:CH₂Cl₂ to give **3** (1.29 g, 85 %). ¹H NMR (CDCl₃-CD₃OD, 400 MHz) δ 7.99 (1H, d, *J* = 9.6 Hz, H-4), 6.23 (1H, s, H-8), 6.16 (1H, d, *J* = 2.4 Hz, H-6), 6.00 (1H, d, *J* = 9.6 Hz, H-3); ¹³C NMR (CDCl₃) δ 163.4, 161.9, 156.5, 155.9, 140.4, 108.4, 102.8, 98.4, 94.6; MS *m/z* 179.04 [M + H]⁺ (calcd. for C₉H₆O₄+H, 179.03).

5-Hydroxyseselin (4), 7-hydroxyalloxanthyletin (5) and dipetalolactone (6): To a solution of 5,7-dihydroxycoumarin (3) (1.5 g, 8.4 mmol) in dry pyridine (3.0 mL) was added 3-methyl-2-butenal (1.7 mL, 17.6 mmol) and the reaction mixture was stirred for 4 h at 115 °C. Then, the reagents were removed under reduced pressure. The solid residue was submitted to flash column chromatography with gradient elution of MeOH:CH₂Cl₂ (0.1-5.0 %) to afford 5-hydroxyseselin (4) (411 mg, 20 %) as the major product, 7-hydroxyalloxanthyletin (5) (164 mg, 8 %) and dipetalolactone (6) (156 mg, 6 %) and 50 % recovered starting material.

5-Hydroxyseselin (4): ¹H NMR (CDCl₃-CD₃OD, 400 MHz) δ 7.96 (1H, d, *J* = 9.6 Hz, H-4), 6.71 (1H, d, *J* = 10 Hz, H-3'), 6.12 (1H, s, H-6), 6.04 (1H, d, *J* = 9.6 Hz, H-3), 5.5 (1H, d, *J* = 10 Hz, H-4'), 1.38 (6H, s, 2CH₃); ¹³C NMR δ 162.5, 157.3, 155.1, 150.8, 140.1, 127.2, 114.9, 109.2, 103.4, 101.9, 98.9, 77.7, 27.9; MS *m/z* 245.08 [M + H]⁺ (calcd. for C₁₄H₁₂O₄+H, 245.08).

7-Hydroxyalloxanthyletin (5): ¹H NMR (CDCl₃-CD₃OD, 400 MHz) δ 7.91 (1H, d, *J* = 9.6 Hz, H-4), 6.57 (1H, d, *J* = 10 Hz, H-3'), 6.25 (1H, s, H-8), 6.00 (1H, d, *J* = 9.2 Hz, H-3), 5.47 (1H, d, *J* = 10 Hz, H-4'), 1.39 (6H, s, 2CH₃); ¹³C NMR δ 162.8, 157.0, 156.3, 150.7, 139.6, 127.1, 116.2, 109.5, 106.1, 102.9, 95.0, 77.7, 27.8; MS *m/z* 245.08 [M + H]⁺ (calcd. for C₁₄H₁₂O₄+H, 245.08).

Dipetalolactone (6): ¹H NMR (CDCl₃, 400 MHz) δ 7.93 (1H, d, *J* = 9.6 Hz, H-4), 6.78 (1H, d, *J* = 10 Hz, H-4'), 6.61 (1H, d, *J* = 10 Hz, H-4''), 6.11 (1H, d, *J* = 9.6 Hz, H-3), 5.57 (1H, d, *J* = 10 Hz, H-3'), 5.54 (1H, d, *J* = 10 Hz, H-3''), 1.45 (6H, s, 2CH₃); ¹³C NMR δ 161.3, 151.9, 150.1, 138.8, 127.7, 127.5, 115.9, 115.2, 110.6, 105.9, 103.2, 102.3, 78.0, 28.2, 28.1; MS *m/z* 311.13 [M + H]⁺ (calcd. for C₁₉H₁₈O₄+H, 311.13).

5-Prenyloxyseselin (7): A mixture of 5-hydroxyseselin (4) (300 mg, 1.22 mmol), K₂CO₃ (765 mg, 9.5 mmol), 3,3-dimethylallyl bromide (0.2 mL, 1.73 mmol) and acetone (20 mL) was refluxed with stirring for 1 h. The solvent was evaporated and the residue was partitioned between EtOAc and brine, the organic layer was washed with 5 % Na₂CO₃, brine, dried and evaporated. The residue was purified by flash column chromatography with 90 % CH₂Cl₂: hexane and gave 5-

prenyloxyseselin (7) (340 mg, 89 %). ¹H NMR (CDCl₃, 400 MHz) δ 7.95 (1H, d, *J* = 9.6 Hz, H-4), 6.76 (1H, d, *J* = 10 Hz, H-3'), 6.20 (1H, s, H-6), 6.07 (1H, d, *J* = 9.6 Hz, H-3), 5.54 (1H, d, *J* = 10 Hz, H-4'), 5.47 (1H, br t, H-2''), 4.52 (2H, d, *J* = 6.4 Hz, H-1''), 1.78 (6H, s, 2CH₃), 1.43 (6H, s, 2CH₃); ¹³C NMR δ 161.4, 157.3, 155.9, 151.1, 139.3, 139.0, 127.4, 118.6, 115.0, 110.2, 103.9, 102.5, 96.3, 77.9, 28.1, 25.8, 18.2; MS *m/z* 313.14 [M + H]⁺ (calcd. for C₁₉H₂₀O₄+H, 313.14).

7-Prenyloxyalloxanthyletin (8): Compound **8** (60 mg, 96 %) was synthesized with the same procedure as compound **7**. ¹H NMR (CDCl₃, 400 MHz) δ 7.93 (1H, d, *J* = 9.6 Hz, H-4), 6.12 (1H, d, *J* = 10 Hz, H-3'), 6.32 (1H, br s, OH), 6.12 (1H, d, *J* = 9.6 Hz, H-3), 5.52 (1H, d, *J* = 10 Hz, H-4'), 5.43 (1H, br t, H-2''), 4.54 (2H, d, *J* = 5.6 Hz, H-1''), 1.74 (6H, s, 2CH₃), 1.43 (6H, s, 2CH₃); ¹³C NMR δ 161.6, 157.6, 155.7, 150.2, 138.6, 127.4, 118.8, 116.3, 110.9, 106.7, 103.6, 96.3, 92.5, 77.6, 65.7, 27.9, 25.7, 18.3; MS *m/z* 313.14 [M + H]⁺ (calcd. for C₁₉H₂₀O₄+H, 313.14).

5-Acetoxy-6-(1,1-dimethylallyl)seselin (9): A mixture of 5-prenyloxyseselin (7) (340 mg, 1.09 mmol), NaOAc (465 mg, 9.7 mmol) and Ac₂O (10 mL, excess) was refluxed with stirring for 20 h. The cooled mixture was filtered and washed with EtOAc. The combined filtrates were evaporated and purified by flash column chromatograph with 5 % EtOAc: hexane to give 5-acetoxy-6-(1,1-dimethylallyl)seselin (9) (365 mg, 94 %). ¹H NMR (CDCl₃, 400 MHz) δ 7.41 (1H, d, *J* = 9.6 Hz, H-4), 6.84 (1H, d, *J* = 10 Hz, H-3'), 6.25 (1H, dd, *J* = 17.4, 10.6 Hz, H-2''), 6.20 (1H, d, *J* = 9.6 Hz, H-3), 5.73 (1H, d, *J* = 10 Hz, H-4'), 4.92 (1H, d, *J* = 17.4 Hz, H-3''b), 4.86 (1H, d, *J* = 10.6 Hz, H-3''a), 2.20 (3H, s, OAc), 1.50 (6H, s, 2CH₃), 1.25 (6H, s, 2CH₃); ¹³C NMR δ 169.4, 160.4, 155.7, 149.1, 148.9, 144.8, 138.4, 129.6, 125.4, 115.1, 113.0, 108.2, 106.9, 106.9, 78.4, 41.1, 27.8, 21.1; MS *m/z* 355.15 [M + H]⁺ (calcd. for C₂₁H₂₂O₅+H, 355.15).

7-Acetoxy-8-(1,1-dimethylallyl)alloxanthyletin (10): Compound **10** (65 mg, 97 %) was synthesized in the same procedure as compound **9**. ¹H NMR (CDCl₃, 400 MHz) δ 8.03 (1H, d, *J* = 9.6 Hz, H-4), 6.27 (1H, dd, *J* = 17.4, 10.6 Hz, H-2''), 6.28 (1H, d, *J* = 9.6 Hz, H-3), 6.13 (1H, d, *J* = 10 Hz, H-3'), 5.61 (1H, d, *J* = 10 Hz, H-4'), 4.96 (1H, d, *J* = 17.4 Hz, H-3''b), 4.89 (1H, d, *J* = 10.6 Hz, H-3''a), 2.24 (3H, s, OAc), 1.61 (6H, s, 2CH₃), 1.55 (6H, s, 2CH₃); ¹³C NMR δ 168.9, 160.2, 153.4, 148.8, 148.6, 147.3, 138.4, 130.0, 120.3, 116.1, 113.4, 110.8, 108.1, 107.2, 77.8, 41.1, 21.1; MS *m/z* 355.15 [M + H]⁺ (calcd. for C₂₁H₂₂O₅+H, 355.15).

5-Hydroxy-6-(1,1-dimethylallyl)seselin (11): The solution of 5-acetoxy-6-(1,1-dimethylallyl)seselin (9) (365 mg, 1.03 mmol) in MeOH (5 mL) and 1 % NaOH in MeOH (8.2 mL, 2.06 mmol) was stirred at room temperature for 3 h. The solution was neutralized with 5 % HCl then evaporated and the residue was partitioned between EtOAc and brine. The EtOAc layer was washed with brine, dried, evaporated and the residue was submitted to flash column chromatography (CH₂Cl₂ to 5 % EtOAc:CH₂Cl₂) to give 5-hydroxy-6-(1,1-dimethylallyl)seselin (11) (310 mg, 97 %). ¹H NMR (CDCl₃, 400 MHz) δ 7.88 (1H, d, *J* = 9.6 Hz, H-4), 6.74 (1H, d, *J* = 10 Hz, H-3'), 7.25 (1H, br s, OH), 6.63 (1H, dd, *J* = 17.8, 10.4 Hz, H-2''), 6.03 (1H, d, *J* = 9.6 Hz, H-3), 5.51 (1H, d, *J* = 10

Hz, H-4'), 5.42 (1H, d, $J = 17.8$ Hz, H-3''b), 5.33 (1H, d, $J = 10.4$ Hz, H-3''a), 1.57 (6H, s, 2CH₃), 1.47 (6H, s, 2CH₃); ¹³C NMR δ 161.4, 155.9, 152.1, 149.5, 149.4, 139.8, 127.1, 115.6, 115.2, 113.6, 110.8, 103.7, 103.3, 77.7, 41.1, 27.6, 27.5; MS m/z 313.14 [M + H]⁺ (calcd. for C₁₉H₂₀O₄+H, 313.14).

7-Hydroxy-8-(1,1-dimethylallyl)alloxanthyletin (12):

Compound **12** (55 mg, 96 %) was synthesized with the same procedure as compound **11**. ¹H NMR (CDCl₃, 400 MHz) δ 7.99 (1H, d, $J = 9.6$ Hz, H-4), 7.33 (br s, OH), 6.60 (1H, d, $J = 10$ Hz, H-3'), 6.46 (1H, dd, $J = 18, 10$ Hz, H-2''), 6.12 (1H, d, $J = 9.6$ Hz, H-3), 5.52 (1H, d, $J = 10$ Hz, H-3''a), 5.49 (1H, d, $J = 18$ Hz, H-3''b), 5.40 (1H, d, $J = 10$ Hz, H-4'), 1.68 (6H, s, 2CH₃), 1.55 (6H, s, 2CH₃); ¹³C NMR δ 161.2, 154.3, 153.9, 149.3, 149.1, 139.1, 127.7, 116.5, 113.8, 111.0, 110.0, 106.5, 103.9, 77.5, 41.0, 28.0, 27.6; HRMS m/z 313.1440 [M + H]⁺ (calcd. for C₁₉H₂₀O₄+H, 313.1436).

Nordentatin (13): The solution of 5-hydroxy-6-(1,1-dimethylallyl)seselin (**11**) (300 mg, 0.96 mmol) in MeOH (5 mL) and 1 % NaOH in MeOH (8.2 mL, 2.06 mmol) was stirred at room temperature for 20 h. The solution was neutralized with 5 % HCl then evaporated and the residue was partitioned between EtOAc and brine. The EtOAc layer was washed with brine, dried, evaporated and the residue was submitted to flash column chromatography (CH₂Cl₂ to 5 % EtOAc:CH₂Cl₂) to give nordentatin (**13**) (294 mg, 98 %). Pale yellow amorphous solid; m.p. 179-181 °C, IR (KBr, $\nu_{\max}$, cm⁻¹): 3248, 2974, 1685, 1605, 1588, 1559, 1318, 1178, 1138; ¹H NMR (CDCl₃) δ 8.04 (1H, d, $J = 9.6$ Hz, H-4), 6.55 (1H, d, $J = 9.9$ Hz, H-6), 6.38 (1H, s, OH), 6.27 (1H, dd, $J = 17.4, 10.6$ Hz, H-2'), 6.13 (1H, d, $J = 9.6$ Hz, H-3), 5.67 (1H, d, $J = 9.9$ Hz, H-7), 4.91 (1H, d, $J = 17.4$ Hz, H-3'b), 4.84 (1H, d, $J = 10.6$ Hz, H-3'a), 1.63 (6H, s, C-4' and C-5'), 1.43 (6H, s, 2CH₃-8); ¹³C NMR δ 161.7 (C-2), 156.0 (C-9a), 154.1 (C-1a), 150.0 (C-2'), 146.8 (C-5), 139.5 (C-4), 129.8 (C-7), 116.0 (C-10), 115.2 (C-6), 110.0 (C-3), 108.0 (C-3'), 106.2 (C-5a), 104.0 (C-4a), 77.1 (C-8), 41.0 (C-1'), 29.5 (C-4' and C-5'), 27.3 (2CH₃-8). HRMS m/z 313.1436 [M + H]⁺ (calcd. for C₁₉H₂₀O₄+H, 313.1440).

Bioassay

Cytotoxicity assay: Cytotoxicity assay against human epidermoid carcinoma (KB), breast adenocarcinoma (MCF-7) and human small cell lung cancer (NCI-H187) cell lines were performed employing Resazurin Microplate Assay (REMA)¹² while cytotoxicity assay against Vero cells (African green monkey kidney) was performed by Green Fluorescent Protein (GFP) based assay¹³. Ellipticine was included as a reference substance.

RESULTS AND DISCUSSION

5,7-Dihydroxycoumarin (**3**), obtained from the reaction between phloroglucinol (**1**) and ethyl propiolate (**2**) using ZnCl₂ as a catalyst at 100 °C, was used as the starting material (**Scheme-I**). Alkylation of compound **3** with 3-methylcrotonaldehyde in the presence of pyridine for 4 h provided the mixture of pyranocoumarins **4** (20 %), **5** (8 %) and dipetalolactone (**6**) (6 %) (**Scheme-II**) and 50 % recovered starting material. Prolonging the reaction time or the excess amount of 3-methylcrotonaldehyde led to **6** as a major product¹⁴. Pyranocoumarins **4** and **5** were treated with 3,3-dimethylallyl

Scheme-I: Synthesis of 5,7-dihydroxycoumarin (**3**)

Scheme-II: Synthesis of pyranocoumarins **4**, **5** and **6**

bromide in the presence of K₂CO₃ and yielded O-alkylation products **7** and **8**, respectively (**Scheme-III**). After treatment of **7** and **8** with Ac₂O in the presence of NaOAc, Claisen rearrangement occurred to provide **9** and **10**, respectively, in high yield (**Scheme-IV**). Hydrolysis of acetyl group using 1 % NaOH in MeOH for 3 h furnished the corresponding phenolic compounds 5- and 7-hydroxy pyranocoumarins **11** and **12** in high yield (**Scheme-V**). Saponification and recyclization of **11** using 1 % NaOH in MeOH for 20 h provided nordentatin in 98 % yield.

Scheme-III: O-Alkylation of compounds **4** and **5**

Scheme-IV: Synthesis of acetylated compounds **9** and **10**

In our previous report, the cytotoxicity of nordentatin against cancer cells, NCI-H187 and KB cell, showed the IC₅₀ values ranging from 3-6 mg/mL and it exhibited cytotoxicity against normal cells, Vero cells, with an IC₅₀ of 17.60 mg/mL⁵. Unfortunately, nordentatin was found in a small amount in a natural source as usual and we tried to synthesize this compound for the other biological activities testing. Moreover, all adducts from each steps were also evaluated for cytotoxicity as well (Table-1). It was found that some of them were natural compounds which showed some activities.

Compound **4** showed cytotoxicity against KB cells with an IC₅₀ value of 3.94 mg/mL while it showed weak activity against the other cell lines. This means the structure of coumarin

Scheme-V: Synthesis of nordentatin

4 displayed selective cytotoxicity against KB cells. On the other hand, compound **5** showed moderate to weak activity against all cell lines. The results showed convincingly that the hydroxyl group at the C-5 position may play an important role in cytotoxicity. Coumarin **6** exhibited cytotoxicity against NCI-H187 cell line with an IC_{50} value of 5.18 mg/mL while it showed weak cytotoxicity to the other cell lines. It seems that this compound is selectively active on the NCI-H187 cell line. Coumarin **7** showed cytotoxicity against NCI-H187 cell line with an IC_{50} value of 5.78 mg/mL which stronger than the starting compound **4**. This may be explained that the prenyl group is favorable to the NCI-H187 cells. In contrast, the cytotoxicity of compound **7** showed weak activity against KB cell line with an IC_{50} value of 17.34 mg/mL. It means that the prenyl group at the C-5 position is selectively active on only the NCI-H187 cell line. In contrast to compound **7**, compound **8** is inactive against the NCI-H187 cell line which means prenyl group at the C-7 position appears to be detrimental to the activity against this cell line. However, compound **8** exhibited stronger cytotoxicity than the parent **5**. It seems that prenyl group at the C-7 position is selectively active on the KB cell line. Acetoxy derivative **9** showed the same cytotoxicity as the parent **7** against the NCI-H187 and KB cell lines but showed stronger activity against the MCF-7 and Vero cell lines. On the other hand, compound **10** exhibited inactive against all cell lines. The results show convincingly that the positions of pyrano, acetoxy and 1,1-dimethylallyl groups are essential for cytotoxicity. Compounds **11** and **12** showed the same activity against all cell lines with IC_{50} of around 13-26 μ g/mL. Considering the cytotoxicity of all derivatives against the NCI-H187 cell line, compounds **6**, **7**, **9** and **13** showed strong cytotoxicity with IC_{50} ranging of 3-7 μ g/mL. Unfortunately, the rest of the derivatives showed moderate to weak cytotoxicity. Comparing between compounds **11** and **13**, it is suggested that the linear skeleton of coumarin is favorable for cytotoxicity against cancer cell lines. Cytotoxicity of all derivatives displayed moderate to inactive against the MCF-7 cell line, although nordentatin showed cytotoxic activity with an IC_{50} value of 10.68 μ g/mL.

Interestingly, coumarin **4** showed cytotoxic activity against the KB cell line with an IC_{50} value of 3.94 μ g/mL and showed very weak activity against Vero cells (IC_{50} = 47.04 μ g/mL). The results show convincingly that this compound is likely to be useful as a lead compound for the development of cytotoxic agents. In addition, compound **7** showed cytotoxicity against the NCI-H187 cell line with an IC_{50} value of 5.78 mg/mL and exhibited non-cytotoxicity against the normal cell (Vero cells). The results indicate that coumarin **7** may be one of the new lead compounds for the development as anticancer agents.

Conclusion

Eleven coumarins derivatives were synthesized and evaluated for cytotoxicity against cancer cells (KB, NCI-H187 and MCF-7) and also normal cell (Vero cell). It was found that compounds **6**, **7**, **9** and **13** exhibited strong cytotoxicity against NCI-H187 cell lines. For the KB cell line, compounds **4** and **13** showed strong cytotoxicity against this cell line. Interestingly, compounds **4** and **7** may be one of the new lead compounds for the development of anticancer agents.

ACKNOWLEDGEMENTS

The National Research University Project of Thailand through the Advanced Functional Materials Cluster of Khon Kaen University and the Center of Excellence for Innovation in Chemistry (PERCH-CIC), Office of the Higher Education Commission, Ministry of Education are gratefully acknowledged for financial support. Thanks are also due to The Bioassay Laboratory of the National Center for Genetic Engineering and Biotechnology, Pathumthani, Thailand, for biological activity assays.

REFERENCES

1. C. Yenjai and S. Wanich, *Bioorg. Med. Chem. Lett.*, **20**, 2821 (2010).
2. U. Songsiang, S. Pitchuanom, C. Boonyarat, C. Hahnvanawong and C. Yenjai, *Eur. J. Med. Chem.*, **45**, 3794 (2010).
3. T. Thongthoom, P. Promsuwan and C. Yenjai, *Eur. J. Med. Chem.*, **46**, 3755 (2011).
4. C. Yenjai, S. Sripontan, P. Sriprajun, P. Kittakoo, A. Jintasirikul, M. Tanticharoen and Y. Thebtaranonth, *Planta Med.*, **66**, 277 (2000).
5. U. Songsiang, T. Thongthoom, C. Boonyarat and C. Yenjai, *J. Nat. Prod.*, **74**, 208 (2011).
6. T. Thongthoom, U. Songsiang, C. Phaosiri and C. Yenjai, *Arch. Pharm. Res.*, **33**, 675 (2010).
7. K. Noipha, T. Thongthoom, U. Songsiang, C. Boonyarat and C. Yenjai, *Diabetes Res. Clin. Pract.*, **90**, e67 (2010).
8. T. Nakamura, N. Kodama, Y. Arai, T. Kumamoto, Y. Higuchi, C. Chaichantipiyuth, T. Ishikawa, K. Ueno and S. Yano, *J. Nat. Med.*, **63**, 21 (2009).
9. Z. Luo, L. Boonyaratanakornkit, C.T. Che, C.A.J. Erdelmeier, H.H.S. Fong and N.R. Farnsworth, *J. Nat. Prod.*, **6**, 1161 (1986).
10. Y.Y. Chan, C.H. Li, Y.C. Shen and T.S. Wu, *Chem. Pharm. Bull.*, **58**, 61 (2010).
11. A. Murakami, G. Gao, M. Omura, M. Yano, C. Ito, H. Furukawa, D. Takahashi, K. Koshimizu and H. Ohigashi, *Bioorg. Med. Chem. Lett.*, **10**, 59 (2000).
12. E. Melliou, P. Magiatis, S. Mitaku, A. Skaltsounis, E. Chinou and I. Chinou, *J. Nat. Prod.*, **68**, 78 (2005).
13. J.O. Brien, I. Wilson, T. Orton and F. Pognan, *Eur. J. Biochem.*, **267**, 5421 (2000).
14. L. Hunt, M. Jordan, M. De Jesus and F.M. Wurm, *Biotechnol. Bioeng.*, **65**, 201 (1999).